Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : Bhvn save search
Global Spinal Muscular Atrophy Treatment Market Report 2022: Sector to Reach $11.4 Billion by 2028 at a 17.8% CAGR
Published: 2023-01-09 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.12%
H: 0.0%
C: -2.55%
PFE A | $25.615 0.89% 9.9M
|
Health Technology
|
| O: -1.71%
H: 0.42%
C: -3.32%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.76%
H: 0.26%
C: -3.27%
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 0.35%
H: 9.67%
C: 3.25%
SRRK A | $13.94 -0.07% 130K
|
Health Technology
|
| O: 1.5%
H: 2.42%
C: -0.11%
PTCT | $25.33 2.59% 220K
|
Health Technology
|
| O: 0.1%
H: 10.44%
C: 5.66%
IONS | $41.07 0.64% 140K
|
Health Technology
|
| O: -0.17%
H: 0.84%
C: -7.91%
treatment global report market muscular atrophy
US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine
Published: 2022-05-23 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 0.25%
H: 1.91%
C: 0.92%
treatment fda drug application review migraine
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Published: 2022-04-27 (Crawled : 12:00) - biospace.com/
PFE A | $25.615 0.89% 9.9M
|
Health Technology
|
| O: -0.37%
H: 1.63%
C: 1.28%
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -4.64%
H: 3.6%
C: 0.93%
vydura treatment granted migraine authorization
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Published: 2022-02-25 (Crawled : 13:00) - biospace.com/
PFE A | $25.615 0.89% 9.9M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
treatment migraine positive chmp
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
Published: 2022-02-25 (Crawled : 13:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
treatment order bioscience platform
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Published: 2022-02-14 (Crawled : 12:30) - biospace.com/
PFE A | $25.615 0.89% 9.9M
|
Health Technology
|
| O: -1.89%
H: 1.36%
C: -0.04%
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 0.27%
H: 2.86%
C: 1.95%
treatment trial migraine china topline results positive results topline
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports
Published: 2022-02-03 (Crawled : 14:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -5.9%
H: 2.59%
C: 2.26%
nurtec treatment long term migraine report
NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine
Published: 2021-11-17 (Crawled : 14:30) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
treatment migraine approval
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
Published: 2021-10-27 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 0.21%
H: 0.1%
C: -3.26%
treatment phase 1 therapy antibody trial phase 1b enroll
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
Published: 2021-10-05 (Crawled : 12:15) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 3.9%
H: 2.03%
C: -3.89%
treatment migraine
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -0.14%
H: 2.85%
C: -0.58%
treatment europe migraine therapy
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
Published: 2021-07-07 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 16.08%
H: 2.25%
C: -2.18%
treatment migraine ev
FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment
Published: 2021-05-27 (Crawled : 22:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -0.01%
H: 2.56%
C: 2.0%
treatment fda migraine fda approval
National Headache Foundation Survey Shows Majority of People with Migraine are Unable to Control Disease and Dissatisfied with Current Preventive Treatment Options
Published: 2021-05-11 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -3.94%
H: 6.79%
C: 5.79%
disease treatment migraine
Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine
Published: 2021-03-11 (Crawled : 14:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 2.38%
H: 4.18%
C: 2.68%
treatment migraine approval
Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine
Published: 2021-03-10 (Crawled : 22:03) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 1.54%
H: 0.95%
C: -7.25%
israel treatment migraine approval
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
Published: 2020-12-16 (Crawled : 14:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: 1.4%
H: 1.19%
C: -0.28%
treatment lancet
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.